Dobutamine-atropine stress echocardiography and dipyridamole sestamibi scintigraphy for the detection of coronary artery disease: limitations and concordance  by Smart, Steven C et al.
Stress Testing
Dobutamine-Atropine Stress Echocardiography
and Dipyridamole Sestamibi
Scintigraphy for the Detection of Coronary
Artery Disease: Limitations and Concordance
Steven C. Smart, MD, FACC,* Aneeta Bhatia, MD,† Robert Hellman, MD,‡
Thomas Stoiber, MD, FACC,† Arthur Krasnow, MD,‡ B. David Collier, MD,‡
Kiran B. Sagar, MD, FACC†
La Crosse and Milwaukee, Wisconsin
OBJECTIVES We sought to compare dobutamine-atropine stress echocardiography (DASE) and dipyrid-
amole Technetium 99-m (Tc-99m) sestamibi single photon emission computed tomography
(SPECT) scintigraphy (DMIBI) for detecting coronary artery disease (CAD).
BACKGROUND Both DASE and DMIBI are effective for evaluating patients for CAD, but their concordance
and limitations have not been directly compared.
METHODS To investigate these aims, patients underwent multistage DASE, DMIBI and coronary
angiography within three months. Dobutamine-atropine stress echocardiography and stress-
rest DMIBI were performed according to standard techniques and analyzed for their accuracy
in predicting the extent of CAD. Segments were assigned to vascular territories according to
standard models. Angiography was performed using the Judkin’s technique.
RESULTS The 183 patients (mean age: 60 6 11 years, including 50 women) consisted of 64 patients
with no coronary disease and 61 with single-, 40 with two- and 18 with three-vessel coronary
disease. Dobutamine-atropine stress echocardiography and DMIBI were similarly sensitive
(87%, 104/119 and 80%, 95/119, respectively) for the detection of CAD, but DASE was
more specific (91%, 58/64 vs. 73%, 47/64, p , 0.01). Sensitivity was similar for the detection
of CAD in patients with single-vessel disease (84%, 51/61 vs. 74%, 45/61, respectively) and
multivessel disease (91%, 53/58 vs. 86%, 50/58, respectively). Multiple wall motion
abnormalities and perfusion defects were similarly sensitive for multivessel disease (72%,
42/58 vs. 66%, 38/53, respectively), but, again, DASE was more specific than DMIBI (95%,
119/125 vs. 76%, 95/125, respectively, p , 0.01). Dobutamine-atropine stress echocardiog-
raphy and DMIBI were moderately concordant for the detection and extent of CAD (Kappa
0.47, p , 0.0001) but were only fairly (Kappa 0.35, p , 0.001) concordant for the type of
abnormalities (normal, fixed, ischemia or mixed).
CONCLUSIONS Dobutamine-atropine stress echocardiography and DMIBI were comparable tests for the
detection of CAD. Both were very sensitive for the detection of CAD and moderately
sensitive for the extent of disease. The only advantage of DASE was greater specificity,
especially for multivessel disease. Dobutamine-atropine stress echocardiography may be
advantageous in patients with lower probabilities of CAD. (J Am Coll Cardiol 2000;36:
1265–73) © 2000 by the American College of Cardiology
Dipyridamole Technetium 99-m (Tc-99m) sestamibi single
photon emission computed tomographic (SPECT) scintig-
raphy (DMIBI) and dobutamine-atropine stress echocardi-
ography (DASE) are common tests for the evaluation of
patients with known or suspected coronary artery disease
(CAD) with limited exercise capacity (1–36). Dipyridamole
Tc-99m sestamibi SPECT scintigraphy detects distur-
bances in resting myocardial perfusion and coronary flow
reserve (2,37). Coronary artery disease is identified by fixed
or reversible perfusion defects (2,37). In contrast, DASE
detects alterations in resting myocardial function and de-
mand ischemia-induced dysfunction (20). Coronary artery
disease is identified by resting wall motion abnormalities
(myocardial scarring, fixed dysfunction with wall thinning
and increased echogenicity) and/or induced wall motion
abnormalities (20).
Both DMIBI and DASE have been compared with other
noninvasive test modalities for the detection of CAD but
not to each other (1,3,5,9–12,16,24–30,32–35). Regional
abnormalities on both techniques have been shown to
correlate with the location of coronary artery stenoses by
coronary angiography (8,10,15,16,19,20,23–25,34). Each
technique has been shown to be safe, even in patients with
acute myocardial infarction (MI), abdominal aortic aneu-
rysms, severe ischemic cardiomyopathies and left main
CAD (15,38–41). Knowledge of the relative limitations
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and concordance of the two tests will be useful in patient
management.
The aim of this study is to directly compare the accuracy
and limitations of DMIBI and DASE in the detection of
the presence and extent of CAD. To investigate this aim
and their concordance, we enrolled 183 consecutive patients
who underwent DMIBI, DASE and coronary angiography.
METHODS
Patient selection. Patients with known or suspected CAD
underwent DASE, DMIBI and coronary angiography
within three months of each other at Froedtert Memorial
Lutheran Hospital or the Zablocki Veterans Affairs Hospi-
tal in Milwaukee, Wisconsin between July, 1992 and June,
1996. All gave informed consent. Exclusion criteria were:
recent MI (,1 month), unstable angina, hypertension
(systolic blood pressure . 220 mm Hg), hypotension
(,90 mm Hg), pregnancy or age #18 years. One patient
was excluded due to poor acoustic windows.
Dobutamine infusion. Beta-adrenergic antagonists were
not stopped before the test. The 5 min stages of dobutamine
infusion were 10, 20, 30 and 40 mg/kg/min in patients with
normal resting wall motion and 5, 10, 20, 30 and
40 mg/kg/min in those with resting wall motion abnormal-
ities (36). Intravenous atropine (0.2 to 0.4 mg every 2 min
to a maximum of 2 mg) was infused to achieve target heart
rates if:
1) heart rate was submaximal at a maximal dose of dobut-
amine or
2) cyclic variability in heart rate .10 beats per min,
hyperdynamic wall motion (end-systolic left ventricular
diameter , 1 cm) or nausea with retching occurred at
submaximal doses of dobutamine.
A 12-lead electrocardiogram and blood pressure were
monitored (36). End points were: maximum dose, heart rate
$85% of age predicted maximum, limiting chest pain,
headaches, vomiting, hypotension (systolic blood pressure
,90 mm Hg), hypertension (systolic pressure $
240 mm Hg), ventricular tachycardia (.5 complexes at
cycle lengths ,600 ms) or sustained supraventricular tachy-
arrhythmias (23,36). Esmolol (0.1 to 0.5 mg/kg intrave-
nously every 2 min up to 1.5 mg/kg) or nitroglycerin
(0.4 mg sublingually every 5 min up to three doses) were
administered after stopping the infusion if chest pain was
severe or did not resolve in #4 min.
Six echocardiographic views (parasternal long and short
axis, apical four-chamber, two-chamber, long axis and short
axis) were videotaped at rest and at each stage (36). Images
were digitized online at rest, 5 or 10 mg/kg/min, peak dose
and recovery with a CineView (Tomtec Imaging, Louisville,
Colorado) R-wave triggered acquisition system and stored
in a quad screen, continuous loop format on 3.5-inch floppy
or optical discs (36,41).
Echocardiographic analysis. The digitized echocardio-
graphic images were analyzed by two experienced readers
without knowledge of clinical, electrocardiographic or an-
giographic data (36,41). When there was disagreement, a
third investigator viewed the images, and differences were
resolved by consensus. Videotape recordings were not rou-
tinely used but were available. Images were analyzed accord-
ing to the previously described 16 segment model and
scoring system (1 5 normal, 2 5 hypokinetic, 3 5 akinetic,
4 5 dyskinetic) (9). Inadequately visualized segments were
not scored. All studies were technically adequate.
Segments were assigned to coronary vascular territories
according to known distributions. Global wall motion score
index was calculated by the standard formula (36). An
abnormal response was defined as:
1) fixed, abnormal wall thickening in $2 contiguous seg-
ments at rest without change at low or peak dose;
2) mixed, resting wall motion abnormality with worsening
or a new abnormality in $2 segments at peak dose; or
3) ischemia, normal resting wall motion with a induced
wall motion abnormality in $2 contiguous segments
(36).
A normal response was defined as a progressive increase
in wall thickening from rest to peak dose.
DMIBI. The dipyridamole infusion protocols used the
standard intravenous dose protocol in the morning in the
fasted state (42). Preinfusion heart rate, 12-lead electrocar-
diogram and blood pressure measurements were obtained in
the supine position and at 2-min intervals thereafter. The
infusion protocol was 0.142 mg/kg/min for 4 min with or
without arm crank exercise for 2 min. Technetium 99-m
sestamibi was infused 3 min after the completion of the
infusion. Cardiac medications were not interrupted, but
methylxanthine-containing medications were withheld for
48 h before these studies. Parenteral aminophylline
(125 mg) was given at the end of the study or when patients
developed severe chest pain, shortness of breath or hypo-
tension. Sublingual nitroglycerin was available to reverse
persistent side effects as needed.
Stress and rest Tc-99m sestamibi SPECT scintigraphy
was performed at 1 h after injecting 370 MBq (10 mCi) and
1,100 MBq (30 mCi) of Tc-99m sestamibi, respectively
Abbreviations and Acronyms
CAD 5 coronary artery disease
DASE 5 dobutamine-atropine stress echocardiography
DMIBI 5 dipyridamole Technetium-99m sestamibi
single photon emission computed
tomographic scintigraphy
LAD 5 left anterior descending coronary artery
LCX 5 left circumflex coronary artery
MI 5 myocardial infarction
RCA 5 right coronary artery
SPECT 5 single photon emission computed
tomography
Tc-99m 5 Technetium 99-m
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(42). All patients were encouraged to eat a fatty meal after
the stress injection to promote bile flow and increase the
liver and gallbladder clearance of activity. Single photon
emission computed tomography was performed by acquir-
ing 32 projections over 180° (from 45° RAO to 135° LAO)
on a circular, 400-mm field of view gamma camera equipped
with a high-resolution collimator interfaced to a computer.
All data were stored in 64 3 64 matrixes. After prefiltering
by a Butterworth filter with a frequency cut-off of 0.4
cycles/cm and an order of 5, filtered back-projection with a
Ramp filter was done to form transaxial sections 6-mm (one
pixel) thick. Data was obliquely reoriented using 6 mm
slices into 12 mm (two pixel) thick slices in three orthogonal
planes (seven to eight slices from apex to base in the short
axis and five to six in the vertical and horizontal long axis
planes). Acquisition time per projection was 40 and 20 s for
stress and rest studies, respectively. Intensity was maximized
for rest and stress images to the hottest pixel in each image
set. All planar images from the stress and rest studies were
photographed along with the reconstructed SPECT images.
Planar images were used to document patient movement
and evaluate extracardiac uptake.
Myocardial territories were evaluated by the same 16
segment model used in echocardiographic analysis (36,42).
The long axis of the left ventricle was divided into basal,
mid and apical thirds, the apex into four segments (septal,
anterior, lateral and inferior) and the mid and basal thirds
into six segments (septal, anterior septal, anterior, lateral,
posterior and inferior). Landmarks were the connections of
the right ventricle to the left ventricle. Segmental uptake
was defined as: normal (maximal and a score of 1); mildly
reduced (normal thickness with slightly reduced uptake,
score 2); moderately reduced (normal thickness with signif-
icantly reduced, but easily discernible, uptake, score 2.5);
severely reduced (only a rim of activity with barely detect-
able uptake, score 3); or absent (no visually apparent uptake,
score 4).
Images were reviewed by two independent expert observ-
ers using both radiographic film and computerized displays
of corresponding rest and stress oblique tomograms. A
perfusion defect was defined as decreased activity in $2
segments in poststress images. Perfusion defects were sub-
classified as: 1) fixed, a resting defect in $2 contiguous
segments that did not change after dipyridamole infusion; 2)
mixed, resting defect with worsening of $1 grade or a new
defect in $2 segments after dipyridamole; or 3) ischemia,
normal resting perfusion with new defects in $2 contiguous
segments after dipyridamole. Apical segments were counted
as defects only when contiguous segments were abnormal. A
high correlation (96%) has been previously reported be-
tween expert visual analysis of defect extent and quantitative
analysis of the SPECT images (32). The average segmental
uptake score was calculated at rest and peak stress for all
segments and each perfusion territory. The percentage of
segments with abnormal uptake and ischemia was also
calculated for each patient and each perfusion territory.
Coronary angiography. Coronary angiography was per-
formed by the Judkin’s technique. Results were analyzed by
an experienced angiographer without knowledge of the
clinical and echocardiographic data. Percent luminal diam-
eter stenosis of all coronary stenoses was determined by the
caliper technique (36). The diameter of the most stenotic
region was compared with the most normal-appearing
region proximal to the stenosis. The criterion for coronary
stenosis was $50% luminal diameter stenosis of any epicar-
dial coronary artery or major branch.
Statistical analysis. Chi-square analysis or Fisher exact test
was used to compare categorical DASE and DMIBI data
(43). A Student paired t test was used to compare the size
and severity of abnormalities of the two tests and identify
differences. Continuous data are reported as mean 6 stan-
dard deviation. Correlations among quantitative coronary
angiography, DASE and DMIBI data were evaluated using
the Kappa statistic (True Epistat software, Richardson,
Texas) and the Fisher z test (43). Kappa values ,0.00 are
indicative of poor concordance, 0.00 to 0.20 of slight
concordance, 0.21 to 0.40 of fair concordance, 0.41 to 0.60
of moderate concordance, 0.61 to 0.80 of substantial con-
cordance and 0.81 to 1.00 of almost perfect concordance.
Differences were considered significant at a two-tailed p
,0.05.
RESULTS
Patient data. The 183 study patients consisted of 133 male
and 50 female patients with a mean age of 60 6 11 years.
Testing was done for typical angina pectoris in 48 patients
(26%), atypical chest pain in 99 (54%), assessment of the
significance of known CAD in 18 (10%) and preoperative
screening in 18 (10%). Medical therapy included aspirin in
53 patients (29%), beta-adrenergic blocking agents in 49
(27%), calcium channel blockers in 73 (40%), diuretics in 31
(17%), digoxin in 14 (8%), nitrates in 41 (22%) and diuretics
in 31 (17%). Dobutamine-atropine echocardiography and
DMIBI were performed before angiography in 165, after
angiography in 15 and one before and the other after
angiography in three.
Coronary angiography. Significant CAD was detected in
119 patients (65%). There were 64 patients with no CAD
(35%) and 61 (33%) with single-, 40 (22%) with two- and
18 (10%) with three-vessel disease. The 61 patients with
single-vessel disease consisted of 18 with left anterior
descending coronary artery (LAD), 30 with right coronary
artery (RCA) and 13 with left circumflex coronary artery
(LCX) disease. The 40 patients with two-vessel disease
consisted of 17 with RCA and the LCX, 16 with LAD and
the RCA and 7 with LAD and the LCX disease.
Dobutamine echocardiographic data. Resting heart rate
and resting blood pressure were 71 6 13 beats/min and
128 6 21 mm Hg, respectively. The mean peak dose was
31 6 12 mg/kg/min. Atropine was used in 78 (43%). Peak
heart rate and blood pressure were 127 6 17 beats/min and
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145 6 33 mm Hg, respectively. Patients tolerated the
procedure well without sustained ventricular tachycardia or
MI. Only four patients rated the side effects as intolerable
(dyspnea in one, chest pain in two and nausea in one).
Wall motion abnormalities were detected in 110 patients
(60%) including 18 (10%) fixed, 50 (27%) mixed and 42
(23%) ischemic abnormalities. The 110 patients with wall
motion abnormalities consisted of 62 (34%) in one, 28
(15%) in two and 20 (11%) in all three vascular territories.
The 62 single abnormalities were located in the LAD
territory in 18 patients, the RCA in 32 and the LCX in 12.
The 28 dual wall motion abnormalities were located in the
RCA and LCX territories in 15 patients, the LAD and
RCA in 9 patients and the LAD and the LCX in 4 patients.
DMIBI. Hemodynamics did not change during dipyrida-
mole infusion. There were no episodes of sustained ventric-
ular tachycardia, prolonged chest pain or hypotension or
MI. Only two patients rated the side effects as intolerable
(chest pain in one and flushing in one).
Perfusion defects were detected in 112 patients (61%)
including 17 (9%) fixed, 48 (26%) mixed and 47 (26%)
ischemic defects. The 112 patients with perfusion defects
consisted of 44 (24%) with defects in one, 38 (21%) in two
and 30 (16%) in three vascular territories. The 44 single
perfusion defects were located in the LAD territory in 18
patients, the RCA in 20 and the LCX in 4. The 38 dual
defects were located in the RCA and LCX territories in 16
patients, the LAD and the RCA in 19 and the LAD and
the LCX in 3.
Detection of CAD. The sensitivity and specificity of
DASE and DMIBI for the detection of CAD by at least
one abnormality are listed in Table 1. Both tests were
sensitive, but DASE was more specific. Both tended to be
more sensitive in multivessel than in single-vessel disease
and were least sensitive in single-vessel LCX disease. The
sensitivity was similar in all subsets of patients with single-
or multivessel coronary disease. False positive DASE oc-
curred only in the inferior wall (6), while the false positive
DMIBI occurred in all myocardial regions (15 anterior/
septal and 11 inferior/posterior/lateral).
Detection of multivessel CAD. Abnormalities in multiple
vascular territories during DASE and DMIBI were mod-
erately sensitive for multivessel CAD (Table 1), but DASE
was more specific (p , 0.01). The sensitivity of the tests was
similar in all angiographic subsets. Both were more sensitive
(p , 0.05) in three-vessel than they were in two-vessel
disease. Multiple wall motion abnormalities did not occur in
patients without disease and were rare in single-vessel
Table 1. Accuracy for the Detection of CAD According to Extent of Disease
Extent of CAD
DASE DMIBI
Sensitivity
% (n)
Specificity
% (n)
Sensitivity
% (n)
Specificity
% (n)
Detection of CAD by an abnormality in any territory
All patients 87 (104/119) 91 (58/64)* 80 (95/119) 73 (47/64)
Single-vessel CAD 84 (51/61) 74 (45/61)
Single-vessel RCA 83 (25/30) 70 (21/30)
Single-vessel LAD 100 (18/18) 89 (16/18)
Single-vessel LCX 62 (8/13) 62 (8/13)
Multivessel CAD 91 (53/58) 86 (50/58)
Two-vessel CAD 93 (37/40) 83 (33/40)
LCX & RCA 94 (16/17) 82 (14/17)
LAD & RCA 94 (15/16) 75 (12/16)
LAD & LCX 86 (6/7) 100 (7/7)
Three-vessel CAD 89 (16/18) 94 (17/18)
Multivessel disease by abnormalities in multiple vascular territories
All Patients 72 (42/58) 95 (119/125)* 66 (38/58) 76 (95/125)
No CAD 100 (64/64)* 88 (56/64)
Single-vessel CAD 90 (55/61)* 64 (39/61)
Single-vessel RCA 83 (25/30) 60 (18/30)
Single-vessel LAD 94 (17/18)* 61 (11/18)
Single-vessel LCX 100 (13/13) 77 (10/13)
Multivessel CAD 72 (42/58) 66 (38/58)
Two-vessel CAD 68 (27/40) 58 (23/40)
LCX & RCA 71 (12/17) 65 (11/17)
LAD & RCA 75 (12/16) 50 (8/16)
LAD & LCX 43 (3/7) 57 (4/7)
Three-vessel CAD 83 (15/18) 83 (15/18)
Detection of CAD in each vascular territory
LAD 69 (43/59) 94 (116/124)* 64 (41/59) 75 (95/124)
RCA 86 (69/81) 92 (92/102)* 70 (59/81) 79 (76/102)
LCX 69 (36/55) 89 (114/128) 63 (32/55) 79 (105/128)
*p , 0.05 vs. DMIBI.
CAD 5 coronary artery disease; DASE 5 dobutamine-atropine stress echocardiography; DMIBI 5 dipyridamole sestamibi scintigraphy; LAD 5 left anterior descending
coronary artery; LCX 5 left circumflex coronary artery; n 5 number of patients; RCA 5 right coronary artery.
1268 Smart et al. JACC Vol. 36, No. 4, 2000
DASE and Dipyridamole Sestamibi for CAD October 2000:1265–73
disease. Multiple perfusion defects were more common
(p , 0.05) than multiple wall motion abnormalities in
patients without disease and were common in single-vessel
disease.
The accuracy of the tests for the detection of disease in
specific vascular territories are also listed in Table 1.
Dobutamine atropine stress echocardiography was more
specific than DMIBI in the LAD and RCA vascular
territories. The specificity of the two tests was similar in the
LCX vascular territory. The sensitivities of the tests were
similar all vascular territories.
Comparison of the extent and severity of abnormalities.
Table 2 compares the size, extent of ischemia and severity of
the perfusion defects on DMIBI to that of wall motion
abnormalities at DASE. Overall, the differences were the
larger size, greater severity and larger extent of ischemia of
perfusion defects in patients without CAD and the greater
severity of wall motion abnormalities in patients with
two-vessel RCA and LCX disease. In the LAD vascular
territory, the only difference was the larger size, greater
severity and larger extent of ischemia of perfusion defects in
patients without CAD. In the RCA vascular territory, the
differences were the greater severity of perfusion defects in
patients with single-vessel LAD and the greater severity of
wall motion abnormalities in patients with RCA and LCX
disease. In the LCX vascular territory, the difference was the
larger size, greater severity and larger extent of ischemia of
perfusion defects in patients with single-vessel LAD and
RCA disease and no disease. Ischemia was more common
on DMIBI in patients with two-vessel disease, but defect
size and severity was similar. No differences were noted in
patients with three-vessel disease.
Concordance. Concordance data for the extent and char-
acter of abnormalities are presented in Table 3. There was
moderate concordance among DASE, DMIBI and coro-
nary angiography for the extent of CAD. The concordance
was moderate in those without disease and those with
multivessel disease but was only fair in those with single-
vessel disease. The concordance was only fair for the type of
abnormalities. The concordance was moderate in those
without CAD but was only fair in those with single-vessel
and multivessel disease. Mixed or ischemic abnormalities
were similarly common in patients with CAD but were
more common on DMIBI in those without disease.
Intra- and inter-observer variability. Intra- and inter-
observer variability of wall motion analysis was minimal in a
representative subset of 60 patients including 40 patients
with and 20 patients without CAD. The interpretations of
the two investigators regarding the presence or absence of
any or multiple wall motion abnormalities agreed in 92%
(55/60) and 90% (54/60), respectively. Intra-observer vari-
ability was assessed by one investigator. The two readings
were concordant regarding the presence or absence of any or
multiple wall motion abnormalities in 97% (58/60) and 95%
(57/60), respectively.
Intra- and inter-observer variability of the sestamibi
scintigraphic data was also minimal in a representative
subset of 60 patients, including 40 patients with and 20
patients without CAD. The interpretations of the two
investigators regarding the presence or absence of any or
multiple perfusion defects agreed in 93% (56/60) and 92%
(55/60), respectively. Intra-observer variability was assessed
by one investigator in a subset of 30 patients. The two
readings were concordant regarding the presence or absence
of any or multiple perfusion defects in 97% (29/30) and 93%
(28/30), respectively.
DISCUSSION
Previous studies. In patients with known or suspected
CAD who are not able to perform an exercise stress test,
available noninvasive modalities include thallium-201 scin-
tigraphy, Tc-99m sestamibi scintigraphy and echocardiog-
raphy with dipyridamole, adenosine, atrial pacing or dobut-
amine with atropine (1–36). High-dose dobutamine and
atropine produce demand ischemia through both chrono-
tropic and inotropic effects (20). In contrast, dipyridamole
and adenosine preferentially vasodilate normal coronary
segments to create a steal or relative hypoperfusion in
arteries with flow limiting stenosis (2,4).
Technetium 99-m sestamibi is becoming the stress ra-
dionuclide of choice due to its sharper image quality and
more flexible scanning properties (1–17). Planar and
SPECT dipyridamole (0.56 to 0.82 mg/kg) Tc-99m sesta-
mibi scintigraphy is accurate for CAD (1–17). Single
photon emission computed tomography imaging enhances
sensitivity (7). Sensitivity has been shown to be consistently
high at 80% to 100%, but specificity has been more variable
at 28% to 100%. Other studies have shown that DMIBI is
accurate for the extent of CAD and the presence or absence
of lesions in specific vascular territories (8,10,15,16).
Echocardiography is another commonly used modality to
detect CAD by exercise and pharmacologic stress tests
(18–36). Dobutamine stress echocardiography is accurate
for CAD (18–36). The addition of atropine may enhance
sensitivity, especially in patients treated with beta-blockers
(22). Sensitivities have ranged from 54% to 96% and
specificities from 66% to 100% (18–36). Doses of up to 50
mg/kg/min of dobutamine and up to 2 mg of atropine have
been safely infused in several safety trials (38 – 41).
Dobutamine-atropine stress echocardiography may also be
accurate for the extent of CAD and the presence or absence
of lesions in specific vascular territories (19,20,23–25,34).
Previous studies have compared DMIBI with dipyrida-
mole SPECT thallium-201 scintigraphy and exercise
SPECT Tc-99m sestamibi scintigraphy (1,3,5,9–12,16).
Sensitivity and specificity were similar for the detection of
CAD. Dobutamine-atropine stress echocardiography has
also been compared with exercise echocardiography, aden-
osine Tc-99m sestamibi SPECT scintigraphy, dobutamine
Tc-99m sestamibi SPECT scintigraphy, dipyridamole
echocardiography and dipyridamole SPECT thallium201
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scintigraphy (24–30,32–35). Sensitivity and specificity were
similar for the detection of CAD, but DASE may be more
specific than dobutamine Tc-99m sestamibi SPECT scin-
tigraphy.
Dipyridamole Tc-99m sestamibi SPECT scintigraphy
has not been compared with DASE. Vasodilator stress may
be a better method to detect hypoperfusion. Dipyridamole is
a commonly used vasodilator stress modality. Previous
studies have not resolved several issues:
1) Do the tests provide comparable data?
2) Are the tests sensitive and specific for the extent of
CAD?
3) Do the tests have the same strengths and limitations?
4) Are there differences in patient tolerance?
Present study. The present study directly compared the
accuracy of DASE and DMIBI for the detection of CAD
and its extent in a set of patients who underwent both tests
and coronary angiography. All studies were performed
within a three-month period. Both tests were tolerated well
without major side effects or complications. Patient toler-
ance was good, and most patients were willing to repeat the
tests. Chest pain tended to be more common with dobut-
amine echocardiography.
The two tests were fairly comparable for the detection of
CAD. Sensitivity was similar for the detection of CAD.
There were no differences in any of the angiographic
subsets. The only difference was the greater specificity of
DASE. In patients without CAD, the difference in speci-
ficity resulted from the more common detection of ischemic
abnormalities by DMIBI in the LAD vascular and LCX
territories. No clinical or hemodynamic factor accounted for
the differences.
The two tests were also fairly comparable for the extent of
CAD. The sensitivity of the two tests was similar in all
angiographic subsets with multivessel CAD. Defect size,
severity and extent of ischemia were similar in patients with
CAD, but ischemia was more commonly detected in the
LCX vascular territory by DMIBI in patients with two-
vessel CAD. The other difference was in specificity. The
lower specificity of DMIBI for multivessel CAD mainly
resulted from the common detection of multiple perfusion
defects in patients with single-vessel CAD. False positive
perfusion defects in remote territories of patients with
single-vessel disease mainly occurred in the RCA and LCX
vascular territories. No clinical or hemodynamic factor
accounted for differences.
The two tests were fairly to moderately concordant. The
tests and angiography were moderately concordant for the
Table 3. Kappa Statistic Correlation of DASE, DMIBI and Angiographic Findings
DASE Extent of CAD DASE Type of WMA
All patients 0 1 2 3 N F I M
0 47 19 4 1 N 47 4 12 8
DMIBI 1 13 23 7 1 DMIBI F 2 3 2 10
Ext of CAD 2 9 12 13 4 Type of Defect I 17 1 20 9
3 4 8 4 14 M 7 10 3 28
K 5 0.47 SE 5 0.043 K 5 0.35 SE 5 0.046
CAD
0 6 14 4 1 N 6 3 8 8
DMIBI 1 5 22 7 1 DMIBI F 1 3 2 10
Ext of CAD 2 3 12 13 4 Type of Defect I 6 1 20 8
3 1 8 4 14 M 2 10 3 28
K 5 0.56 SE 5 0.043 K 5 0.28 SE 5 0.055
SVD
0 5 10 1 0 N 5 1 6 4
DMIBI 1 3 19 1 0 DMIBI F 0 1 1 4
Ext of CAD 2 2 8 3 1 Type of Defect I 5 1 15 3
3 0 8 0 0 M 0 5 1 9
K 5 0.35 SE 5 0.043 K 5 0.32 SE 5 0.076
MVD
0 1 4 3 1 N 1 2 2 4
DMIBI 1 2 3 6 1 DMIBI F 1 2 1 6
Ext of CAD 2 1 4 10 3 Type of Defect I 1 0 5 5
3 1 0 4 14 M 2 5 2 19
K 5 0.50 SE 5 0.043 K 5 0.35 SE 5 0.073
No CAD
0 41 5 0 0 N 41 1 4 0
DMIBI 1 8 1 0 0 DMIBI F 1 0 0 0
Ext of CAD 2 6 0 0 0 Type of Defect I 11 0 0 1
3 3 0 0 0 M 5 0 0 0
K 5 0.57 SE 5 0.043 K 5 0.44 SE 5 0.074
0 5 normal DASE or DMIBI; 1 5 abnormality in one vascular territory; 2 5 abnormalities in two vascular territories; 3 5 abnormalities in three vascular territories; CAD 5
coronary artery disease; DASE 5 dobutamine-atropine stress echocardiography; DMIBI 5 dipyridamole Technetium-99m sestamibi single photon emission computed
tomography scintigraphy; Ext 5 extent; F 5 fixed abnormality; I 5 ischemia with normal resting study; K 5 Kappa statistic; M 5 mixed result (resting abnormality with inducible
ischemia); MVD 5 multivessel disease; N 5 normal DASE or DMIBI; SE 5 standard error; SVD 5 single vessel disease; WMA 5 wall motion abnormality.
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extent of CAD, especially in patients without disease and
those with multivessel disease. Concordance was only fair in
patients with single-vessel disease. In contrast, the concor-
dance between the types of abnormalities (normal, fixed,
ischemia or mixed) was only fair. Concordance was moderate
in patients without CAD but was only fair in those with
single- or multivessel disease. Mixed or ischemic abnormalities
were similarly common in patients with CAD but were more
common on DMIBI in patients without disease.
The tests were feasible in this unselected population.
Only one patient was excluded due to poor acoustic win-
dows. Both tests were least sensitive for disease in patients
with single-vessel LCX disease. False positives occurred in
the all vascular territories for DMIBI but only occurred in
the RCA vascular territory for DASE.
Study limitations. Dobutamine-atropine stress echocardi-
ography, DMIBI and coronary angiography were not done
on the same day. While the interval between studies was up
to three months in some cases, the majority (80%, 146/182)
were performed within one week of each other. None of the
patients had intervening ischemic events. Dipyridamole
Tc-99m sestamibi SPECT scintigraphy did not include
gating. Recent studies have shown that gating for resting
wall motion and ejection fraction and dual isotope imaging
with resting 201Thallium may improve specificity. The
findings of this study may not be applicable to studies using
gating for resting wall motion and ejection fraction, dual
isotope imaging with resting 201Thallium or to protocols
using rest stress SPECT imaging (9). Dobutamine-atropine
stress echocardiography and DMIBI were analyzed by
similar segmental models, but segments may not have been
perfectly matched. These data may have influenced some of
the concordance data for vascular territories but could not
have influenced the results regarding the detection of CAD
or its extent. Finally, concordance data was moderate for the
extent of abnormalities, indicating that this effect was
minor. Thus, the discordance resulted from intrinsic differ-
ences in mechanisms of detection of CAD.
Clinical implications and conclusion. Dobutamine-
atropine stress echocardiography and DMIBI are compara-
ble tests for the detection of CAD. Both are sensitive for the
detection of CAD and moderately sensitive for the presence
of multivessel disease. The only advantage of DASE was its
greater specificity. False positive wall motion abnormalities
only occurred in the RCA vascular territory. Multiple wall
motion abnormalities did not occur in those without disease
and were uncommon in single-vessel disease. In contrast,
false positive perfusion defects occurred in all vascular
territories, and multiple defects were commonly detected in
patients with single-vessel disease. The concordance was
moderate for the extent and severity of abnormalities but
was only fair for the type of defects. Dobutamine-atropine
stress echocardiography may be advantageous in patients
with lower probabilities of CAD.
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